X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Alexa Fluor® 488 anti-mouse CD45.2 antibody

RRID:AB_492868

Antibody ID

AB_492868

Target Antigen

CD45.2 See NCBI gene mouse

Proper Citation

(BioLegend Cat# 109816, RRID:AB_492868)

Clonality

monoclonal antibody

Comments

Applications: FC, IF, IHC

Clone ID

Clone 104

Host Organism

mouse

Vendor

BioLegend Go To Vendor

Cat Num

109816

Publications that use this research resource

Co-inhibitory Molecule B7 Superfamily Member 1 Expressed by Tumor-Infiltrating Myeloid Cells Induces Dysfunction of Anti-tumor CD8+ T Cells.

  • Li J
  • Immunity
  • 2018 Apr 17

Literature context:


Abstract:

The molecular mechanisms whereby CD8+ T cells become "exhausted" in the tumor microenvironment remain unclear. Programmed death ligand-1 (PD-L1) is upregulated on tumor cells and PD-1-PD-L1 blockade has significant efficacy in human tumors; however, most patients do not respond, suggesting additional mechanisms underlying T cell exhaustion. B7 superfamily member 1 (B7S1), also called B7-H4, B7x, or VTCN1, negatively regulates T cell activation. Here we show increased B7S1 expression on myeloid cells from human hepatocellular carcinoma correlated with CD8+ T cell dysfunction. B7S1 inhibition suppressed development of murine tumors. Putative B7S1 receptor was co-expressed with PD-1 but not T cell immunoglobulin and mucin-domain containing-3 (Tim-3) at an activated state of early tumor-infiltrating CD8+ T cells, and B7S1 promoted T cell exhaustion, possibly through Eomes overexpression. Combinatorial blockade of B7S1 and PD-1 synergistically enhanced anti-tumor immune responses. Collectively, B7S1 initiates dysfunction of tumor-infiltrating CD8+ T cells and may be targeted for cancer immunotherapy.

Funding information:
  • Medical Research Council - G0601943(United Kingdom)